57 / 78
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 6, November/December 2017
AFRICA
395
SIL was slightly superior to ILO in treating ischaemic injury was
that it reduced or depleted the NO formed during ischaemia, as
SIL enhances NO-mediated vasodilatation.
In our study, individual administration of SIL (resulting in the
lowest NO levels) and combined administration of ILO and SIL
were observed to cause a decrease in NO levels in comparison to
that found in the ILO alone and ischaemic groups (which had the
highest NO levels). Therefore, we believe that this biochemical
feature of SIL could be used to eliminate ischaemia–reperfusion
injury in the future.
Irisin may contribute to the acceleration of wound recovery,
since heat speeds up chemical reactions and enables rapid
production of the proteins involved in wound healing, thus
promoting rapid recovery. It has recently been reported that
wound healing of human umbilical vein endothelial cells
(HUVEC) was gradually accelerated in groups treated with
10 and 20 nM irisin at both 12 and 24 hours, via increasing
migration and tube formation.
42
The administration of both
drugs in combination did not prove more effective than the
individual administration of each. However, when individual
administrations of ILO and SIL were compared to one another,
SIL was found to be more potent in circumventing ischaemia.
One explanation why SIL was more efficient in ischaemia
treatment may be that since it is an NO-dependent agent, it can
deplete NO arising from ischaemia and therefore reduce the
amount of peroxinitrite originating from NO and causing tissue
injury.
43
Conclusion
In this experimentally induced animal myocardial ischaemia
model, administration of ILO and SIL reduced both ischaemia
and the release of NO, while elevating irisin levels. Our study
showed that even though SIL and ILO have not been routinely
used in the management of myocardial ischaemia–reperfusion,
both drugs are critical pharmaceutical agents in eliminating
tissue ischaemia. Further clinical studies are necessary on
patients to elucidate this phenomenon.
This project was supported by the protocol number TF-1508 of the scientific
research unit of Fırat University, to whom we would like to extend out thanks
for their support. This study was orally presented at the 14th Congress of the
Turkish Society of Cardiovascular Surgery held in Antalya, Turkey, from 3–6
November 2016.
References
1.
Garcia-Dorado D, Oliveras J. Myocardial oedema: a preventable cause
of reperfusion injury?
Cardiovasc Res
1993;
27
(9): 1555–1563.
2.
Kirtane AJ, Parikh PB, Stuckey TD, Xu K, Witzenbichler B, Weisz
G,
et al.
Is there an ideal level of platelet P2Y12-receptor inhibition
in patients undergoing percutaneous coronary intervention? ‘Window’
analysis from the ADAPT-DES study (Assessment of Dual AntiPlatelet
Therapy With Drug Eluting Stents).
J Am Coll Cardiol Cardiovasc Interv
2015;
8
(15): 1978–1987.
3.
Pantazi E, Bejaoui M, Folch-Puy E, Adam R, Roselló-Catafau J.
Advances in treatment strategies for ischemia reperfusion injury.
Expert
Opin Pharmacother
2016;
17
(2): 169–179.
4.
Mayorchak Y, Paterson H, Ryan JB, Byth K, Robinson LM, Kovoor
P,
et al.
Mammary artery to saphenous vein composite T grafts for
coronary artery bypass: late follow-up.
J Cardiovasc Surg (Torino)
2013;
54
(4): 531–536.
5.
Aydin S, Eren MN, Aydin S, Ozercan IH, Dagli AF. The bioactive
peptides salusins and apelin-36 are produced in human arterial and
venous tissues and the changes of their levels during cardiopulmonary
bypass.
Peptides
2012;
37
(2): 233–239.
6.
Aydin S, Aydin S, Nesimi Eren M, Sahin I, Yilmaz M, Kalayci M,
et al.
The cardiovascular system and the biochemistry of grafts used in heart
surgery.
Springerplus
2013;
2
: 612.
7.
Smith FC, Tsang GM, Watson HR, Shearman CP. Iloprost reduces
peripheral resistance during femoro-distal reconstruction.
Eur J Vasc
Surg
1992;
6
(2): 194–198.
8.
Pace-Asciak CR. Novel eicosanoid pathways: the discovery of
prostacyclin/6-keto prostaglandin F1alpha and the hepoxilins.
Mol
Neurobiol
2005;
32
(1): 196.
9.
Kecskér A, Blitstein-Willinger E. Pharmacological activity and local and
systemic tolerance of topically applied iloprost.
Arzneimittelforschung
1993;
43
(4): 450–454.
10. Roy S, Brosstad F, Sakariassen KS. Selective thrombolysis in acute deep
vein thrombosis: evaluation of adjuvant therapy in vivo.
Cardiovasc
Intervent Radiol
1999;
22
(5): 403–410.
11. Arslan M, Donmez T, Erer D, Tatar T, Comu FM, Alkan M. Effect of
iloprost on erythrocyte deformability in rat’s lower extremity undergoing
an ischemia reperfusion injury.
Bratisl Lek Listy
2013;
114
(4): 189–191.
12. Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil
promote erectile function recovery after cavernous nerve injury through
antioxidative mechanisms.
J Sex Med
2007;
4
(4 Pt 1): 908–916.
13. Liu K, Yan M, Zheng X, Yang Y. The dynamic detection of NO during
the ischemic postconditioning against global cerebralischemia/reperfu-
sion injury.
Nitric Oxide
2014;
38
: 17–25.
14. Beck-Broichsitter M, Hecker A, Kosanovic D, Schmehl T, Gessler T,
Weissmann N,
et al.
Prolonged vasodilatory response to nanoencapsu-
lated sildenafil in pulmonary hypertension.
Nanomedicine
2016;
12
(1):
63–68.
15. Ronson RS, Nakamura M, Vinten-Johansen J. The cardiovascular
effects and implications of peroxynitrite.
Cardiovasc Res
1999;
44
(1):
47–59.
16. Beckman JS. -OONO: rebounding from nitric oxide.
Circ Res
2001;
89
(4): 295–297.
17. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of
ischemia/reperfusion injury.
Int Rev Cell Mol Biol
2012;
298
: 229–317.
18. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC,
et al.
A
PGC1-
α
-dependent myokine that drives brown-fat-like development of
white fat and thermogenesis.
Nature
2012;
11
(7382): 463–468.
19. Aydin S. Three new players in energy regulation: preptin, adropin and
irisin.
Peptides
2014;
56
: 94–110.
20. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L,
Rouleau JL,
et al.
Relation between renal dysfunction and cardiovascu-
lar outcomes aftermyocardial infarction.
N Engl J Med
2004;
351
(13):
1285–1295.
21. Thirupurasundari CJ, Jayalakshmi R, Niranjali Devaraj S. Liver archi-
tecture maintenance by tincture of Crataegus against isoproterenol-
induced myocardially infarcted rats.
J Med Food
2005;
8
(3): 400–404.
22. Liu TY, Shi CX, Gao R, Sun HJ, Xiong XQ, Ding L,
et al.
Irisin inhibits
hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/
Akt pathway in type 2 diabetic mice and hepatocytes.
Clin Sci (Lond)
2015;
129
(10): 839–850.
23. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM.
Cardioprotective effect of insulin-like growth factor I in myocardial
ischemia followed by reperfusion.
Proc Natl Acad Sci USA
1995;
92
(17):